Dennis Friedman, MD
Cardiovascular Disease · Rockville, MDNPI 1922036359
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 196 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations.
Across 196 payments — averaging $33.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$883
- Amgen$874
- Esperion Therapeutics, Inc.$573
- E.r. Squibb & Sons, L.L.C.$522
- Abbott$389
- Johnson & Johnson$374
- plus $3K from 28 others
Across 14 payments — averaging $8960.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$63K
- Boehringer Ingelheim International GmbH$33K
- Boehringer Ingelheim Pharma GmbH & Co.kg$29K
What the payments were for
- Food & beverage$6,29097%
- Education$1913%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $883 |
| Amgen | 19 | $874 |
| Esperion Therapeutics, Inc. | 13 | $573 |
| E.r. Squibb & Sons, L.L.C. | 24 | $522 |
| Abbott | 5 | $389 |
| Johnson & Johnson | 12 | $374 |
| Pfizer | 15 | $280 |
| Novo Nordisk | 9 | $279 |
| Boston Scientific | 4 | $273 |
| Merck | 10 | $246 |
| Novartis | 8 | $228 |
| Edwards Lifesciences | 4 | $217 |
| Amarin Pharma, Inc. | 6 | $198 |
| Cvrx, Inc. | 2 | $175 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $139 |
| Kowa Pharmaceuticals America, Inc. | 10 | $132 |
| Irhythm Technologies, Inc. | 1 | $103 |
| Abiomed | 4 | $77 |
| Sanofi-aventis U.S. LLC | 5 | $65 |
| Philips North America LLC | 3 | $62 |
| Inari Medical, Inc. | 2 | $57 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $40 |
| Medtronic | 1 | $35 |
| Lexicon Pharmaceuticals, Inc. | 2 | $34 |
| Kestra Medical Technology Services, Inc. | 2 | $33 |
| Atricure, Inc. | 2 | $32 |
| Astellas Pharma US Inc | 1 | $25 |
| BD | 1 | $23 |
| Scpharmaceuticals Inc. | 1 | $23 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| Bayer | 1 | $19 |
| Boehringer Ingelheim | 1 | $18 |
| Bardy Diagnostics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$498
- Repatha$488
- NEXLIZET$364
- NEXLETOL$364
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$174
- Barostim Neo System$146
- MitraClip System$136
- WATCHMAN Access System$126
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$122
- Vascepa$122
- Ozempic$116
- ENTRESTO$112
- CAMZYOS$105
- Zio monitor$103
- ZIO XT Patch$103
How this compares
$6,481 in reported general payments places this provider in the 75th percentile of 507 cardiovascular disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 246 | $372,961 |
| EntrestoSacubitril/Valsartan | 100 | $157,272 |
| XareltoRivaroxaban | 85 | $130,104 |
| VascepaIcosapent Ethyl | 119 | $87,907 |
| Repatha SureclickEvolocumab | 55 | $64,503 |
| JardianceEmpagliflozin | 36 | $46,785 |
| NexlizetBempedoic Acid/Ezetimibe | 33 | $33,376 |
| Rosuvastatin Calcium | 956 | $28,808 |
| CrestorRosuvastatin Calcium | 24 | $17,810 |
| Ranolazine ErRanolazine | 105 | $14,802 |
| Ezetimibe | 353 | $13,640 |
| BrilintaTicagrelor | 11 | $11,560 |
| FarxigaDapagliflozin Propanediol | 12 | $9,004 |
| Atorvastatin Calcium | 606 | $8,586 |
| Metoprolol Succinate | 471 | $8,279 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $280 | $372,961246 claims |
| NovartisEntresto | $228 | $157,272100 claims |
| Johnson & JohnsonXarelto | $374 | $130,10485 claims |
| Boehringer IngelheimJardiance | $18 | $46,78536 claims |
| AstraZenecaCrestor, Brilinta, Farxiga | $883 | $38,37347 claims |
| Esperion Therapeutics, Inc.Nexlizet | $573 | $33,37633 claims |
| Kowa Pharmaceuticals America, Inc.Bystolic | $132 | $7,57417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 507 cardiovascular disease providers in Maryland.
Other cardiovascular disease in Rockville
- Mark TurcoRockville$25K
- Dennis DonohueRockville$19K
- Navin KapurBaltimore$1.5M
- Michael BlahaBaltimore$609K
- Sanjay RajagopalanBaltimore$521K
- Allen TaylorN Bethesda$456K
- David GoorayLargo$333K
- Erin MichosBaltimore$257K
- Seth MartinBaltimore$166K
- Erika FellerBaltimore$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.